IntelGenx (TSXV:IGX; OTCQB:IGXT) and Aquestive Therapeutics (NASDAQ:AQST), its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) entered into a definitive U.S. license and supply agreement with an undisclosed leading men’s health company.
“Securing this commercial partnership is a significant milestone in our innovative collaboration with Aquestive, and represents another major step toward achieving our mutual goal of making Tadalafil oral films available to men suffering from ED and BPH,” Dr. Horst Zerbe, CEO of IntelGenx, said in a statement.
IntelGenx and Aquestive entered into a global collaboration for Tadalafil oral films in 2019.
